BioSpace News Archive

Genethon today announced The Lancet Neurology published online preliminary results of a clinical trial conducted by Astellas Pharma using a gene therapy developed by Genethon for X-linked myotubular myopathy, a rare genetic muscle disease affecting 1 in 50,000 newborn boys.

Cofactor Genomics, the company bridging the precision medicine gap, today announced successful validation of the OncoPrism immunotherapy predictive diagnostic assay, enabling physicians to use the test to help guide treatment decisions for patients with metastatic or recurrent squamous cell carcinoma of the head and neck (HNSCC).

The global process chromatography market size was valued at USD 12.5 billion in 2022 and is projected to surpass around USD 27.87 billion by 2032, expanding at a healthy CAGR of 8.4% from 2023 to 2032.

Owl Therapeutics, a wholly-owned subsidiary of Gryphon Bio, today announced a global licensing and collaboration agreement with Abliva AB of Lund, Sweden, to advance Abliva’s NeuroSTAT® (OWL-1410) for the prevention and treatment of moderate to severe traumatic brain injury (TBI).

MAIA Biotechnology, Inc. announced that it has closed its previously announced registered direct offering for the issuance and sale of an aggregate of 2,424,243 of its shares of common stock at a purchase price of $1.65 per share.

Masimo (NASDAQ: MASI) today announced that the Masimo W1™ medical watch has received FDA 510(k) clearance for over-the-counter (OTC) and prescription use (Rx).

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, reported the grant of 22,765 restricted stock units of the company’s common stock to eight newly hired non-executive officers of the company.

Iovance Biotherapeutics, Inc. announced that on November 16, 2023, the Company approved the grant of inducement stock options covering an aggregate of 59,950 shares of Iovance’s common stock to nine new non-executive employees.

Biophytis SA announced that it has received written notification from the Nasdaq Stock Market LLC dated November 15, 2023, indicating that, based upon a closing bid price of less than $1.00 per share for the Company’s American Depositary Shares for the prior 30 consecutive business days period, the Company no longer satisfies Nasdaq Listing Rule 5550.

FORE Biotherapeutics reported updated safety and efficacy data from the Phase 1/2a clinical trial evaluating plixorafenib, a novel, investigational, small-molecule, next-generation, orally available selective inhibitor of BRAF alterations.